Newton, MA – According to filings with the U.S. Securities and Exchange Commission, Alcresta Therapeutics is raising $19,999,998.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Anastasios Konidaris played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Alcresta Therapeutics

Alcresta Therapeutics is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency or fat malabsorption, which results in malabsorption common in cystic fibrosis, digestive cancers, preterm birth, and other serious diseases.

To learn more about Alcresta Therapeutics, visit http://www.alcresta.com/

Contact:
Anastasios Konidaris, Chief Financial Officer
617-431-3600
akonidaris@alcresta.com
https://www.linkedin.com/in/anastasios-tasos-konidaris-99992731/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved